Santhera signs deal with Ipsen

Santhera Pharmaceuticals and Ipsen have announced a license agreement for the development and commercialization of fipamezole for territories outside of North America and Japan. The compound is currently under investigation for the treatment of levodopa-induced dyskinesia in Parkinson’s Disease. Initiation of a first Phase III study by Biovail is scheduled for 2011. The agreement stipulates a data sharing, under which Ipsen has the right to use these data for its own purposes. Under the agreement, Ipsen acquired the rights to fipamezole outside the United States, Canada and Japan for an upfront payment of €13 million and additional payments contingent to future development, regulatory and sales milestones of up to €128 million. In addition, Santhera is entitled to royalty payments on Ipsen’s future net sales.

Advertisement